Insider Trading Alert - CNBKA, GNMK And LCUT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 18, 2015, 71 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $77.50 to $28,170,000.00.

Highlighted Stocks Traded by Insiders:

Century Bancorp (CNBKA) - FREE Research Report

Filler James J, who is 10% Owner at Century Bancorp, bought 2 shares at $38.75 on June 18, 2015. Following this transaction, the 10% Owner owned 417,756 shares meaning that the stake was boosted by 0% with the 2-share transaction.

The shares most recently traded at $38.83, up $0.08, or 0.21% since the insider transaction. Historical insider transactions for Century Bancorp go as follows:

  • 4-Week # shares bought: 7,865
  • 12-Week # shares bought: 18,320
  • 24-Week # shares bought: 28,297

The average volume for Century Bancorp has been 3,000 shares per day over the past 30 days. Century Bancorp has a market cap of $140.4 million and is part of the financial sector and banking industry. Shares are down 2.65% year-to-date as of the close of trading on Thursday.

Century Bancorp, Inc. operates as the bank holding company for Century Bank and Trust Company that provides banking products and services to commercial enterprises, state and local governments and agencies, nonprofit organizations, and individuals in Massachusetts. The stock currently has a dividend yield of 1.23%. The company has a P/E ratio of 9.9.

Exclusive Offer: Get the latest Stock Analysis on CNBKA - FREE

TheStreet Quant Ratings rates Century Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Century Bancorp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GenMark Diagnostics (GNMK) - FREE Research Report

Hawkins Jeffrey Alan, who is SVP, Global Marketing & PM at GenMark Diagnostics, sold 442 shares at $9.13 on June 18, 2015. Following this transaction, the SVP, Global Marketing & PM owned 116,436 shares meaning that the stake was reduced by 0.38% with the 442-share transaction.

Williams Jennifer Anne, who is SVP, Human Resources at GenMark Diagnostics, sold 543 shares at $9.11 on June 18, 2015. Following this transaction, the SVP, Human Resources owned 152,939 shares meaning that the stake was reduced by 0.35% with the 543-share transaction.

Gleeson Michael, who is SVP, North American Com. Ops. at GenMark Diagnostics, sold 537 shares at $9.17 on June 18, 2015. Following this transaction, the SVP, North American Com. Ops. owned 182,333 shares meaning that the stake was reduced by 0.29% with the 537-share transaction.

Stier Eric, who is SVP & General Counsel at GenMark Diagnostics, sold 234 shares at $9.10 on June 18, 2015. Following this transaction, the SVP & General Counsel owned 40,752 shares meaning that the stake was reduced by 0.57% with the 234-share transaction.

The shares most recently traded at $10.21, up $1.11, or 10.87% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 9,527
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 16,052
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 124,104

The average volume for GenMark Diagnostics has been 199,700 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $384.7 million and is part of the health care sector and health services industry. Shares are down 32.92% year-to-date as of the close of trading on Thursday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. Currently, there are 5 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings rates GenMark Diagnostics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full GenMark Diagnostics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Lifetime Brands (LCUT) - FREE Research Report

Winoker Laurence, who is SVP- Finance, CFO & Treasurer at Lifetime Brands, sold 1,962 shares at $15.00 on June 18, 2015. Following this transaction, the SVP- Finance, CFO & Treasurer owned 8,483 shares meaning that the stake was reduced by 18.78% with the 1,962-share transaction.

The shares most recently traded at $15.25, up $0.25, or 1.64% since the insider transaction. Historical insider transactions for Lifetime Brands go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 11,375
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 26,875
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 82,872

The average volume for Lifetime Brands has been 48,400 shares per day over the past 30 days. Lifetime Brands has a market cap of $206.1 million and is part of the consumer goods sector and consumer durables industry. Shares are down 13.55% year-to-date as of the close of trading on Thursday.

Lifetime Brands, Inc. designs, sources, and sells branded kitchenware, tableware, and other products used in the home in the United States and internationally. The company operates through three segments: U.S. Wholesale, International, and Retail Direct. The stock currently has a dividend yield of 1.01%. The company has a P/E ratio of 82.6. Currently, there are no analysts who rate Lifetime Brands a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCUT - FREE

TheStreet Quant Ratings rates Lifetime Brands as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and disappointing return on equity. Get the full Lifetime Brands Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists